Drug Profile
DEN 181
Alternative Names: CEN-181; Curcusome-RA; CurcusomeTM-RA; DEN-181Latest Information Update: 05 Jan 2022
Price :
$50
*
At a glance
- Originator University of Queensland
- Developer Dendright
- Class Anti-inflammatories; Immunotherapies
- Mechanism of Action Immunosuppressants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- No development reported Rheumatoid arthritis; Type 1 diabetes mellitus
Most Recent Events
- 05 Nov 2021 Updated immunogenicity data from a phase I trial in Rheumatoid arthritis presented at the ACR Convergence 2021
- 28 Dec 2020 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(Adjunctive treatment) in Australia (SC, Injection)
- 13 Nov 2019 Dendright completes a phase I trial in Rheumatoid arthritis (Adjunctive treatment) in Australia (SC) (ACTRN12617001482358)